Drug Trial Radar · NCT03374657
A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa
Last checked: Nov 19, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Aug 22, 2018
Primary completion
May 12, 2026
Study completion May 12, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 15, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this first-in-human study is to explore the maximum tolerated dose (MTD) of CPK850 as determined by the single ascending dose ranging portion of the study. This study will also evaluate the safety and potential efficacy of CPK850 on improving visual function in patients with decreased visual function from RLBP1 retinitis pigmentosa due to biallelic mutations in the RLBP1 gene.
Conditions
- Retinitis Pigmentosa
Interventions
CPK850Biological
In one of 4 dose levels administered via subretinal injection under anesthesia
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs), serious adverse events (SAEs) and deathsTime frame: Up to Year 5
- Number of responders in dark adaptationTime frame: Screening/baseline up to Year 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.